|Articles|June 27, 2011

Linagliptin cardiovascular safety profile appears superior to glimepiride

Cardiovascular events were fewer in patients with type 2 diabetes randomized to 2 years of the DPP-4 inhibitor linagliptin compared with glimepiride as add-on therapy to metformin, according to data from a phase III study.

Stay informed with the Medical Economics eNewsletter, delivering expert insights, financial strategies, practice management tips, and technology trends tailored for today’s physicians.

Latest CME

Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Linagliptin cardiovascular safety profile appears superior to glimepiride

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Trending on Medical Economics

455 defendants charged in massive $6.5 billion health care fraud takedown

Beyond the exam room: How primary care and community partnerships could transform chronic disease prevention

Why interoperability is shifting from a tech problem to a money problem

Independent practices and Medicare: Why a ‘low-paying’ panel may be your most important asset

Retiring and need income soon? Consider an immediate annuity